Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Other Non-Current Liabilities (2020 - 2026)

Maxcyte has reported Other Non-Current Liabilities over the past 6 years, most recently at $263000.0 for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 4.01% to $263000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $263000.0 through Dec 2025, down 4.01% year-over-year, with the annual reading at $263000.0 for FY2025, 4.01% down from the prior year.
  • Other Non-Current Liabilities was $263000.0 for Q4 2025 at Maxcyte, up from $25000.0 in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $1.3 million in Q4 2022 and troughed at $25000.0 in Q3 2025.
  • The 5-year median for Other Non-Current Liabilities is $351500.0 (2022), against an average of $581150.0.
  • Year-over-year, Other Non-Current Liabilities skyrocketed 232.93% in 2023 and then tumbled 90.97% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $450200.0 in 2021, then surged by 193.2% to $1.3 million in 2022, then tumbled by 78.56% to $283000.0 in 2023, then decreased by 3.18% to $274000.0 in 2024, then fell by 4.01% to $263000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Other Non-Current Liabilities are $263000.0 (Q4 2025), $25000.0 (Q3 2025), and $248000.0 (Q2 2025).